Screener
Celldex Therapeutics CLDX Total Current Assets
Total Current Assets at other companies
Other financials
Where this comes from
Reported directly by Celldex Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AssetsCurrent.
The source filing: Celldex Therapeutics’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:06 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001104659-26-091984
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Marketable securities | 670,133 | 489,702 |
| Accounts and other receivables | 230 | 2,015 |
| Prepaid and other current assets | 7,114 | 14,076 |
| Total current assets | 724,931 | 534,664 |
| Property and equipment, net | 9,756 | 5,334 |
| Operating lease right-of-use assets, net | 5,038 | 2,437 |
| Intangible assets | 27,190 | 27,190 |
| Other assets | 15,434 | 13,358 |
Item 1. Unaudited Financial Statements
FAQ
- What is Celldex Therapeutics's total current assets?
- Celldex Therapeutics (CLDX) reported total current assets of $724.93M in Q2 2026.
- How has Celldex Therapeutics's total current assets changed year-over-year?
- Celldex Therapeutics's total current assets increased by 11.8% year-over-year, from $648.4M to $724.93M.
- What is the long-term trend for Celldex Therapeutics's total current assets?
- Over 5 years (2020 to 2025), Celldex Therapeutics's total current assets has grown at a 22.0% compound annual growth rate (CAGR), from $197.84M to $534.66M.
- What does total current assets mean?
- The sum of all assets expected to be converted to cash or consumed within one year — cash, receivables, inventory, and prepaid expenses.
Ask your AI about Celldex Therapeutics's total current assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude